   |
|
SYMPOSIUM |
|
| Year : 2013 | Volume
: 58
| Issue : 3 | Page : 219-224 |
|
| Pharmacology of antihistamines
|
|
|
Martin K Church1, Diana S Church2
1 Allergie Centrum Charité/ECARF, Charité Universitätsmedizin Berlin, Germany
2 Highlands Medical Centre, Fareham, Hampshire, Germany
| Date of Web Publication | 20-Apr-2013 |
Correspondence Address:
Martin K Church
Department of Dermatology and Allergy, Charité Universitätsmedizin Berlin, Charitéplatz 1, D 10117 Berlin
Germany
 Source of Support: Martin Church has been a
speaker or consultant for Almirall, FAES Pharma, Menarini, MSD, UCB Pharma,
Sanofi-Aventis, and Uriach. Diana Church has no conflict of interest., Conflict of Interest: None  | Check |
DOI: 10.4103/0019-5154.110832
|
|
 Abstract | | |
H 1- antihistamines, the mainstay of treatment for urticaria, were developed from anticholinergic drugs more than 70 years ago. They act as inverse agonists rather than antagonists of histamine H 1 -receptors which are members of the G-protein family. The older first generation H 1- antihistamines penetrate readily into the brain to cause sedation, drowsiness, fatigue and impaired concentration and memory causing detrimental effects on learning and examination performance in children and on impairment of the ability of adults to work and drive. Their use should be discouraged. The newer second-generation H 1 -antihistamines are safer, cause less sedation and are more efficacious. Three drugs widely used for symptomatic relief in urticaria, desloratadine, levocetirizine and fexofenadine are highlighted in this review. Of these levocetirizine and fexofenadine are the most potent in humans in vivo. However, levocetirizine may cause somnolence in susceptible individuals, whereas fexofenadine has a relatively short duration of action and may be required to be given twice daily for all round daily protection. Although desloratadine is less potent, it has the advantages of rarely causing somnolence and having a long duration of action.
Keywords: Cetirizine, desloratadine, fexofenadine, H 1 -antihistamines, hydroxyzine, levocetirizine, loratadine
How to cite this article:
Church MK, Church DS. Pharmacology of antihistamines
. Indian J Dermatol 2013;58:219-24 |
| Introduction | |  |
To understand H 1 -antihistamines, it is necessary to appreciate the state of science in the 1930s. In his review about his own work, [1] Daniel Bovet wrote "Three naturally occurring amines, acetylcholine, epinephrine, and histamine, may be grouped together because they have a similar chemical structure, are all present in the body fluids, and exert characteristically strong pharmacologic activities. There are alkaloids which interfere with the effects of acetylcholine. Similarly, there are sympatholytic poisons which neutralize or reverse the effects of epinephrine. It seemed possible to me, therefore, that some substance might exist which exerts a specific antagonism toward histamine." It was against this background that Bovet, who was looking for antagonists of acetylcholine, asked his student, Anne-Marie Staub, to test some of these compounds against histamine. This led to the discovery of the first H 1 -antihistamine in 1937. [2] Although this compound was too toxic for use in humans, it opened the door for the introduction into the clinic of antergan in 1942, [3] followed by diphenhydramine in 1945 [4] and chlorpheniramine, brompheniramine, and promethazine later the same decade. [5]
The histamine H 1 -receptor
The histamine H 1 -receptor is a member of the superfamily of G-protein-coupled receptors (GPCRs) [Figure 1]a. GPCRs may be viewed as "cellular switches" which exist as an equilibrium between the inactive or "off" state and the active or "on" state. [6] In the case of the histamine H 1 -receptor, histamine cross links sites on transmembrane domains III and V to stabilize the receptor in its active conformation, thus causing the equilibrium to swing to the "on" position [7] [Figure 1]b. H 1 -antihistamines, which are not structurally related to histamine, do not antagonize the binding of histamine but bind to different sites on the receptor to produce the opposite effect. For example, cetirizine cross links sites on transmembrane domains IV and VI to stabilize the receptor in the inactive state and swing the equilibrium to the "off" position [8] [Figure 1]c. Thus, H 1 -antihistamines are not receptor antagonists, but are inverse agonists in that they produce the opposite effect on the receptor to histamine. [6] Consequently, the preferred term to define these drugs is "H 1 -antihistamines" rather than "histamine antagonists."
The development of H 1 -antihistamines | Figure 1: (a) Diagram of a histamine H1-receptor in a membrane showing seven transmembrane domains. Histamine stimulates the receptor following its penetration into the central core of the receptor. (b) A surface view of an activated receptor with histamine linking domains III and V. (c) A surface view of an inactive receptor with cetirizine linking domains IV and VI
Click here to view |
Bearing in mind that first-generation H 1 -antihistamines derive from the same chemical stem from which cholinergic muscarinic antagonists, tranquilizers, antipsychotics, and antihypertensive agents were also developed, it is hardly surprising that they have poor receptor selectivity and often interact with receptors of other biologically active amines causing antimuscarinic, anti-α-adrenergic, and antiserotonin effects. But perhaps their greatest drawback is their ability to cross blood-brain barrier and interfere with histaminergic transmission. Histamine is an important neuromediator in the human brain which contains approximately 64,000 histamine-producing neurons, emanating from the tuberomammillary nucleus. [9] Stimulation of H 1 -receptors in all of the major parts of the cerebrum, cerebellum, posterior pituitary and spinal where they increase arousal in the circadian sleep/wake cycle, reinforce learning and memory, and have roles in fluid balance, suppression of feeding, control of body temperature, control of cardiovascular system, and mediation of stress-triggered release of adrenocorticotropic hormone (ACTH) and b-endorphin from the pituitary gland. [10] It is not surprising then that antihistamines crossing the blood-brain barrier interfere with all of these processes.
Physiologically, the release of histamine during the day causes arousal, whereas its decreased production at night results in a passive reduction in the arousal response. When taken during the day, first-generation H 1 -antihistamines, even in the manufacturers' recommended doses, frequently cause daytime somnolence, sedation, drowsiness, fatigue, and impaired concentration and memory. [11],[12] When taken at night, first-generation H 1 -antihistamines increase the latency to the onset of rapid eye movement (REM) sleep and reduce the duration of REM sleep. [13],[14],[15] The residual effects of poor sleep, including impairment of attention, vigilance, working memory, and sensory motor performance, are still present in the next morning. [14],[16] This is especially problematical with drugs with a long half-life [Table 1]. The detrimental central nervous system (CNS) effects of first-generation H 1 -antihistamines on learning and examination performance in children and on impairment of the ability of adults to work, drive and fly aircraft have been reviewed in detail in a recent review. [17]
A major advance in antihistamine development occurred in the 1980s with the introduction of second-generation H 1 -antihistamines, [18] which are minimally or nonsedating because of their limited penetration of the blood-brain barrier. In addition, these drugs are highly selective for the histamine H 1 -receptor and have no anticholinergic effects. The latest EAACI/GA 2 LEN/EDF/WAO guidelines for the management of urticaria [19] recommend that the first-line treatment for urticaria should be second generation, nonsedating H 1 -antihistamines. Further, it states "In patients with urticaria and no special indication, we recommend against the routine use of old sedating first-generation antihistamines (strong recommendation, high quality evidence)."
H 1 -antihistamines in urticaria
Most types of urticaria, including chronic spontaneous urticaria and the majority of inducible urticarias, are mediated primarily by mast cell-derived histamine [20] which reaches very high concentrations due to the poor diffusibility of substances in the dermis. [21],[22] They are characterized by short-lived wheals ranging from a few millimeters to several centimeters in diameter which are accompanied by severe itching which is usually worse in the evening or night-time. [23] Standard licensed doses of H 1 -antihistamines are often ineffective in completely relieving symptoms in many patients for whom increasing the dosage up to four-fold is recommended. [19],[24],[25] Thus, it is clear that the attributes that dermatologists seek when choosing an H 1 -antihistamine are: Good efficacy, a rapid onset of action, a long duration of action, and freedom from unwanted effects. Although some of these attributes may be predicted from preclinical and pharmacokinetic studies, it is only in the clinical environment that they may be definitively established.
Efficacy
Two factors determine the efficacy of an H 1 -antihistamine: The affinity of the drug for H 1 -receptors (absolute potency) and the concentration of the drug at the sites of the H 1 -receptors. The affinity of an H 1 -antihistamine for H 1 -receptors is determined in vitro in preclinical studies. Comparing the three most recently developed drugs, desloratadine is the most potent antihistamine (Ki: 0.4 nM) followed by levocetirizine (Ki: 3 nM) and fexofenadine (Ki: 10 nM) (the lower the concentration, the higher the potency). The drug concentrations at its site of action could, theoretically, be calculated from its apparent volume of distribution (Vd) which are ~49, 0.4, and ~5.6 l/kg for desloratadine, levocetirizine, and fexofenadine, respectively. [26] However, Vd does not take into account other factors which influence local tissue concentrations in vivo, such as absorption, metabolism, and plasma binding. In the study of Gillard and colleagues, [27] concentrations of unbound drug in the plasma rather than Vd were used to calculate receptor occupancy, a theoretical indicator of effectiveness in vivo [Table 2]. The validity of these calculations of receptor occupancy is confirmed by the relative inhibition of wheal and flare responses by these drugs. [26],[28],[29],[30] | Table 2: Comparison of receptor occupancy for desloratadine, fexofenadine, and levocetirizine with inhibition of histamine-induced wheal and flare responses 4 and 24 h after drug administration
Click here to view |
Speed of onset of action and duration of action
The speed of onset of action of a drug is often equated to the rate of its oral absorption and its duration of action by its plasma concentration. However, this is not strictly correct as seen from [Figure 2]. In this study, in children, [31],[32] plasma concentrations of drug are near maximum by 30 min and yet it takes a further 1½ h for the drug to diffuse into the extravascular space to produce a maximal clinical effect. In adults, the maximal inhibition of the flare response is ~4 h for levocetirizine, fexofenadine, and desloratadine [28],[30],[33] but may be longer for drugs, such as loratadine and ebastine, which require metabolism to produce their active moiety. [28] | Figure 2: Diagrammatic representation of the pharmacokinetics and pharmacodynamics of levocetirizine for a single oral dose of levocetirizine[31,32]
Click here to view |
[Figure 2] also shows that the duration of action of levocetirizine in inhibiting the histamine-induced flare response is also much longer than would be predicted from a knowledge of its plasma concentration. [31],[32] This is presumably to "trapping" of the drug by its strong and long-lasting binding to histamine H 1 -receptors. [8] Although less active in the wheal and flare test, desloratadine has a similarly long duration of action. [33] However, the duration of action of fexofenadine, calculated as the time for the wheal to remain inhibited by at least 70%, is less prolonged being 8.5 h for 120 mg fexofenadine compared with 19 h for cetirizine. [34] The primary reason for the shorter duration of action of fexofenadine is that it is actively secreted into the intestine and urine by P-glycoprotein. [35]
Elimination
The metabolism and elimination of H 1 -antihistamines have been extensively reviewed elsewhere [26],[36] and will be only briefly summarized here. Cetirizine and levocetirizine are not metabolized and are excreted primarily unchanged in the urine. [26] Desloratadine undergoes extensive metabolism in liver. Although this gives the potential for drug-drug interactions, no significant interactions have been reported [36] Fexofenadine, which is also minimally metabolized, is excreted primarily in the feces following its active secretion into the intestine under the influence of active drug transporting molecules. [36] This gives the potential for interactions with agents, such as grapefruit juice and St Johns Wort, which inhibit these transporters. Although plasma concentrations of fexofenadine may be increased by these agents, no significant resulting adverse reactions have been reported. [36]
Unwanted effects
Somnolence
A major reason for the reduced penetration of second-generation H 1 -antihistamines into the brain is because their translocation across the blood-brain barrier is under the control of active transporter proteins, of which the ATP-dependent efflux pump, P-glycoprotein, is the best known. [37],[38] It also became apparent that antihistamines differ in their substrate specificity for P-glycoprotein, fexofenadine being a particularly good substrate. [39] In the brain, the H 1 -receptor occupancy of fexofenadine assessed using positron emission tomography (PET) scanning is negligible, <0.1%, and, in psychomotor tests, fexofenadine is not significantly different from placebo. [40] Furthermore, fexofenadine has been shown to be devoid of central nervous effects even at supraclinical doses, up to 360 mg. [41]
Although fexofenadine is devoid of CNS effects, many other second-generation H 1 -antihistamines still penetrate the brain to a small extent where they have the potential to cause some degree of drowsiness or somnolence, particularly when used in higher doses. For example, PET scanning of the human brain has shown that a single oral doses of 10 mg and 20 mg cetirizine caused 12.5% and 25.2% occupancy of the H 1 -receptors in prefrontal and cingulate cortices, respectively. [42] These results would explain the repeated clinical findings that the incidence of drowsiness or fatigue is greater with cetirizine than with placebo. [43],[44],[45],[46] Recent publications have suggested that, at manufacturers' recommended doses, levocetirizine is less sedative than cetirizine [47] and desloratadine causes negligible somnolence. [36],[48] However, it should be pointed out that "mean results" do not reveal everything as some patients may show considerable somnolence, whereas others are unaffected.
Cardiotoxicity
The propensity of astemizole and terfenadine, to block the IKr current, to prolong the QT interval, and to potentially cause serious polymorphic ventricular arrhythmias such as torsades de pointes is well documented. [6],[49] These two drugs are no longer approved by regulatory agencies in most countries. In addition, some first-generation H 1 -antihistamines, such as promethazine, [50] brompheniramine, [51] and diphenhydramine, [52] may also be associated with a prolonged QTc and cardiac arrhythmias when taken in large doses or overdoses. No clinically significant cardiac effects have been reported for the second-generation H 1 -antihistamines: Loratadine, fexofenadine, mizolastine, ebastine, azelastine, cetirizine, desloratadine, and levocetirizine. [53],[54],[55],[56]
| Conclusions | | |
In conclusion, the use of first-generation H 1 -antihistamines should be discouraged in clinical practice today for two main reasons. First, they are less effective than second-generation H 1 -antihistamines. [11],[57],[58] Second, they have unwanted side effects and the potential for causing severe toxic reactions which are not shared by second-generation H 1 -antihistamines. The only exception to this is where severe pruritus is of particular concern where drugs such as hydroxyzine may be of use. [59] Indeed, Simons in her review of antihistamines in children [60] writes that in children with urticaria or atopic dermatitis whose pruritus is very severe, the sedation produced by an old H 1 -antihistamine, such as hydroxyzine, is a benefit rather than a risk.
With regard to second-generation H 1 -antihistamines, there are many efficacious and safe drugs on the market for the treatment of allergic disease. Of the three drugs highlighted in this review, levocetirizine and fexofenadine are the most potent in humans in vivo. However, levocetirizine may cause somnolence in susceptible individuals, whereas fexofenadine has a relatively short duration of action and may be required to be given twice daily for all round daily protection. Although desloratadine is less potent, it has the advantages of rarely causing somnolence and having a long duration of action.
| References | | |
| 1. | Bovet D. Introduction to antihistamine agents and antergan derivative. Ann N Y Acad Sci 1950;50:1089-126. 
|
| 2. | Staub AM, Bovet D. Action de la thymoxyethyldiethylamine (929F) et des ethers phenoliques sur le choc anaphylactique. C R Soc Biol 1937;125:818-21.
|
| 3. | Halpern BN. Les antihistaminiques de synthese. Essais de chemotherapie des etats allergiques. Arch Int Pharmacodyn Ther 1942;681:339-408.
|
| 4. | Loew ER, Macmillan R, Kaiser ME. The anti-histamine properties of benadryl, beta-di-methylaminoethyl benzhydryl ether hydrochloride. J Pharmacol Exp Ther 1946;86:229-38.
|
| 5. | Emanuel MB. Histamine and the antiallergic antihistamines: A history of their discoveries. Clin Exp Allergy 1999;29:1-11.
|
| 6. | Leurs R, Church MK, Taglialatela M. H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-98.
|
| 7. | Wieland K, Laak AM, Smit MJ, Kühne R, Timmerman H, Leurs R. Mutational analysis of the antagonist-binding site of the histamine H (1) receptor. J Biol Chem 1999;274:29994-30000.
|
| 8. | Gillard M, Van Der Perren C, Moguilevsky N, Massingham R, Chatelain P. Binding characteristics of cetirizine and levocetirizine to human H (1) histamine receptors: Contribution of Lys (191) and Thr (194). Mol Pharmacol 2002;61:391-9.
|
| 9. | Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003;4:121-30.
|
| 10. | Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001;63:637-72.
|
| 11. | Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351:2203-17.
|
| 12. | Juniper EF, Ståhl E, Doty RL, Simons FE, Allen DB, Howarth PH. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 2005;115:S390-413.
|
| 13. | Adam K, Oswald I. The hypnotic effects of an antihistamine: Promethazine. Br J Clin Pharmacol 1986;22:715-7.
|
| 14. | Boyle J, Eriksson M, Stanley N, Fujita T, Kumagi Y. Allergy medication in Japanese volunteers: Treatment effect of single doses on nocturnal sleep architecture and next day residual effects. Curr Med Res Opin 2006;22:1343-51.
|
| 15. | Rojas-Zamorano JA, Esqueda-Leon E, Jimenez-Anguiano A, Cintra-McGlone L, Mendoza Melendez MA, Velazquez Moctezuma J. The H1 histamine receptor blocker, chlorpheniramine, completely prevents the increase in REM sleep induced by immobilization stress in rats. Pharmacol Biochem Behav 2009;91:291-4.
|
| 16. | Kay GG, Berman B, Mockoviak SH, Morris CE, Reeves D, Starbuck V, et al. Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch Intern Med 1997;157:2350-6.
|
| 17. | Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H (1)-antihistamines: A GA (2) LEN position paper. Allergy 2010;65:459-66.
|
| 18. | Holgate ST, Canonica GW, Simons FE, Taglialatela M, Tharp M, Timmerman H, et al. Consensus Group on New-Generation Antihistamines (CONGA): Present status and recommendations. Clin Exp Allergy 2003;33:1305-24.
|
| 19. | Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA (2) LEN/EDF/WAO guideline: Management of urticaria. Allergy 2009;64:1427-43.
|
| 20. | Nuutinen P, Harvima IT, Ackermann L. Histamine, but not leukotriene C4, is an essential mediator in cold urticaria wheals. Acta Derm Venereol 2007;87:9-13.
|
| 21. | Petersen LJ, Church MK, Skov PS. Histamine is released in the wheal but not the flare following challenge of human skin in vivo: A microdialysis study. Clin Exp Allergy 1997;27:284-95.
|
| 22. | Stenken JA, Church MK, Gill CA, Clough GF. How minimally invasive is microdialysis sampling? A cautionary note for cytokine collection in human skin and other clinical studies. AAPS J 2010;12:73-8.
|
| 23. | Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy 2011;66:317-30.
|
| 24. | Wedi B, Kapp A. Chronic urticaria: Assessment of current treatment. Expert Rev Clin Immunol 2005;1:459-73.
|
| 25. | Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007;37:631-50.
|
| 26. | Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004;18:399-411.
|
| 27. | Gillard M, Benedetti MS, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res 2005;54:367-9.
|
| 28. | Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: Suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002;88:190-7.
|
| 29. | Denham KJ, Boutsiouki P, Clough GF, Church MK. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res 2003;52:424-7.
|
| 30. | Purohit A, Melac M, Pauli G, Frossard N. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol 2004;92:635-40.
|
| 31. | Simons FE, Simons KJ. Levocetirizine: Pharmacokinetics and pharmacodynamics in children age 6 to 11 years. J Allergy Clin Immunol 2005;116:355-61.
|
| 32. | Simons KJ, Benedetti MS, Simons FE, Gillard M, Baltes E. Relevance of H1-receptor occupancy to H1-antihistamine dosing in children. J Allergy Clin Immunol 2007;119:1551-4.
|
| 33. | Purohit A, Melac M, Pauli G, Frossard N. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003;56:388-94.
|
| 34. | Purohit A, Duvernelle C, Melac M, Pauli G, Frossard N. Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol 2001;86:387-92.
|
| 35. | Miura M, Uno T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol 2010;6:69-74.
|
| 36. | Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: A comparative review. Clin Pharmacokinet 2008;47:217-30.
|
| 37. | Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36:179-94.
|
| 38. | Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003;31:312-8.
|
| 39. | Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27:866-71.
|
| 40. | Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, et al. Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004;44:890-900.
|
| 41. | Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: A double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002;32:133-9.
|
| 42. | Tashiro M, Kato M, Miyake M, Watanuki S, Funaki Y, Ishikawa Y, et al. Dose dependency of brain histamine H (1) receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [11C] doxepin. Hum Psychopharmacol 2009;24:540-8.
|
| 43. | Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:617-26.
|
| 44. | Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:927-33.
|
| 45. | Salmun LM, Gates D, Scharf M, Greiding L, Ramon F, Heithoff K. Loratadine versus cetirizine: Assessment of somnolence and motivation during the workday. Clin Ther 2000;22:573-82.
|
| 46. | Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "non-sedating" antihistamines: Four prescription-event monitoring studies in general practice. BMJ 2000;320:1184-6.
|
| 47. | De Vos C, Mitchev K, Pinelli ME, Derde MP, Boev R. Non-interventional study comparing treatment satisfaction in patients treated with antihistamines. Clin Drug Investig 2008;28:221-30.
|
| 48. | Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract 2004;58:109-18.
|
| 49. | Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996;36:233-52.
|
| 50. | Jo SH, Hong HK, Chong SH, Lee HS, Choe H. H (1) antihistamine drug promethazine directly blocks hERG K(+) channel. Pharmacol Res 2009;60:429-37.
|
| 51. | Park SJ, Kim KS, Kim EJ. Blockade of HERG K+channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656. J Appl Toxicol 2008;28:104-11.
|
| 52. | Zareba W, Moss AJ, Rosero SZ, Hajj-Ali R, Konecki J, Andrews M. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol 1997;80:1168-73.
|
| 53. | Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children. Drug Saf 2001;24:119-47.
|
| 54. | DuBuske LM. Second-generation antihistamines: The risk of ventricular arrhythmias. Clin Ther 1999;21:281-95.
|
| 55. | Simons FE, Prenner BM, Finn A Jr, Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003;111:617-22.
|
| 56. | Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: Results from a thorough QT study. Eur J Clin Pharmacol 2007;63:1011-7.
|
| 57. | Simons FE. Comparative pharmacology of H1 antihistamines: Clinical relevance. Am J Med 2002;113:38S-46.
|
| 58. | Simons FE, Silver NA, Gu X, Simons KJ. Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol 2002;110:777-83.
|
| 59. | Shohrati M, Davoudi SM, Keshavarz S, Sadr B, Tajik A. Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: A randomized clinical trial. Cutan Ocul Toxicol 2007;26:249-55.
|
| 60. | Simons FE. H1-antihistamines in children. Clin Allergy Immunol 2002;17:437-64.
|
[Figure 1], [Figure 2]
[Table 1], [Table 2] |
|
| This article has been cited by | | 1 |
Growing Utilization of Radical Chemistry in the Synthesis of Pharmaceuticals |
|
| Anjali Gupta, Joydev K. Laha | | The Chemical Record. 2023; | | [Pubmed] | [DOI] | | | 2 |
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor |
|
| Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Harald E. Vonkeman, Martijn B. A. van Doorn, Frank Hoentjen, Michael T. Nurmohamed, Eugene P. van Puijenbroek, Bart J. F. van den Bemt | | BioDrugs. 2023; | | [Pubmed] | [DOI] | | | 3 |
Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via pharmacometrics |
|
| Ji-Hun Jang, Seung-Hyun Jeong, Yong-Bok Lee | | Journal of Pharmaceutical Analysis. 2023; | | [Pubmed] | [DOI] | | | 4 |
Factors Associated with the Use of Over-the-counter Sleep Aids Containing Diphenhydramine: A Cross-sectional Study in Saudi Arabia |
|
| Khalid Alhussain, Dimah I. Almuayli, Sara M. Aldaej | | Saudi Pharmaceutical Journal. 2023; | | [Pubmed] | [DOI] | | | 5 |
Novel H2S-Releasing Bifunctional Antihistamine Molecules with Improved Antipruritic and Reduced Sedative Actions |
|
| Ivi Antoniadou, Maria Georgiou, Yannis Dotsikas, Alexandra Lamprou, Nikolaos Lougiakis, Nicole Pouli, Nikolaos Karousis, Yannis Loukas, Ioulia Tseti, Panagiotis Marakos, Andreas Papapetropoulos | | Journal of Medicinal Chemistry. 2023; | | [Pubmed] | [DOI] | | | 6 |
Aurantio-obtusin alleviates allergic responses in ovalbumin-induced rhinitis |
|
| Mavis Sersah Nyarko, Cynthia Amaning Danquah, Aaron Opoku Antwi | | Scientific African. 2023; : e02004 | | [Pubmed] | [DOI] | | | 7 |
Effectiveness of levocetirizine in treating allergic rhinitis while retaining work efficiency |
|
| Yogesh Dabholkar, Tanush Shah , Roheet Rathod , Akhila Paspulate , Chaitanya Veligandla Krishna , Rahul Rathod , Joshi Devesh Kumar , Bhavesh Kotak | | Archives of Asthma, Allergy and Immunology. 2023; 7(1): 005 | | [Pubmed] | [DOI] | | | 8 |
Standardizing Anaphylaxis Treatment in Pediatric Care Settings |
|
| Sara Anvari, Vibha Szafron, Tanya J. Hilliard, Lisa Forbes-Satter, Mona D. Shah | | Pediatric Quality & Safety. 2023; 8(3): e652 | | [Pubmed] | [DOI] | | | 9 |
The currently available diagnostic tools and treatments of scabies and scabies variants: An updated narrative review |
|
| Jacob Al-Dabbagh, Razan Younis, Nemat Ismail | | Medicine. 2023; 102(21): e33805 | | [Pubmed] | [DOI] | | | 10 |
How to choose an antihistamine drug for patients of special groups? |
|
| Natalia M. Nenasheva, Marina U Peredelskaya, O V Sebekina, Kristina A Akmalova | | Russian Journal of Allergy. 2023; | | [Pubmed] | [DOI] | | | 11 |
Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis |
|
| Aranjit Singh Randhawa, Norhayati Mohd Noor, Mohd Khairi Md Daud, Baharudin Abdullah | | Frontiers in Pharmacology. 2022; 12 | | [Pubmed] | [DOI] | | | 12 |
Allergic Rhinitis: A Clinical and Pathophysiological Overview |
|
| Siti Muhamad Nur Husna, Hern-Tze Tina Tan, Norasnieda Md Shukri, Noor Suryani Mohd Ashari, Kah Keng Wong | | Frontiers in Medicine. 2022; 9 | | [Pubmed] | [DOI] | | | 13 |
Characterization of Loratadine API and Simultaneous Quantification of
Seven Potential Genotoxic Nitrosamine Impurities in Single Method by
LC-MS/MS in Loratadine API and its Dosage Forms |
|
| Gudibanda Chandrasekhar Reddy, Pulipaka Shyamala, Rallabhandi Murali Krishna, Kapavarapu Maruthi Venkata Narayanarao, Mannem Durga Babu | | Asian Journal of Chemistry. 2022; 34(6): 1505 | | [Pubmed] | [DOI] | | | 14 |
Loratadine tablet analyzed by x-ray photoelectron spectroscopy |
|
| Sergio A. Rincón-Ortiz, Andrés C. García-Castro, Rogelio Ospina | | Surface Science Spectra. 2022; 29(1): 014024 | | [Pubmed] | [DOI] | | | 15 |
Comparing available treatments for pollen-induced allergic rhinitis in children |
|
| Angela Klain, Cristiana Indolfi, Giulio Dinardo, Fabio Decimo, Maria Angela Tosca, Michele Miraglia Del Giudice, Giorgio Ciprandi | | Expert Review of Clinical Immunology. 2022; : 1 | | [Pubmed] | [DOI] | | | 16 |
Anaphylaxis in Children |
|
| Melisa S. Tanverdi, Alexandria Wiersma, Kristin M. Kim, Allison G. Hicks, Rakesh D. Mistry | | Pediatric Emergency Care. 2022; 38(9): 456 | | [Pubmed] | [DOI] | | | 17 |
Review of potential medical treatments for middle ear cholesteatoma |
|
| Matthias Schürmann, Peter Goon, Holger Sudhoff | | Cell Communication and Signaling. 2022; 20(1) | | [Pubmed] | [DOI] | | | 18 |
Ocular Biodistribution of Once-Daily 0.6% Bilastine Eye Drops Reveals Highest Levels in Conjunctiva Up to 24?h Postadministration |
|
| Inés Torrens, Álvaro Ganza, Gonzalo Hernández, Ana Gonzalo, Arturo Zazpe | | Journal of Ocular Pharmacology and Therapeutics. 2022; | | [Pubmed] | [DOI] | | | 19 |
Clinical Efficacy and Safety of Chinese Herbal Medicine in the Treatment of Uremic Pruritus: A Meta-Analysis of Randomized Controlled Trials |
|
| Ping-Hsun Lu, Chien-Cheng Lai, I-Hsin Lin, Fu-Ming Tsai, Po-Hsuan Lu | | Pharmaceuticals. 2022; 15(10): 1239 | | [Pubmed] | [DOI] | | | 20 |
Assessment of cytotoxicity, genotoxicity, and mutagenicity of the dexchlorpheniramine reference standard and pharmaceutical formula in human peripheral blood mononuclear cells |
|
| Pamella Eduardha Espindola Chaves, Luísa Zuravski, Anelise Santos Soares, Lavínia da Veiga Pereira, Élvio Adilio Serpa, Luís Flávio Souza de Oliveira, Michel Mansur Machado | | Brazilian Journal of Pharmaceutical Sciences. 2022; 58 | | [Pubmed] | [DOI] | | | 21 |
Evaluation of subchronic toxicity of the compound of diphenhydramine hydrochloride and caffeine after 28 days of repeated oral administration in Sprague-Dawley rats and beagle dogs |
|
| Lijun Ren, Lang Yan, Wenjing Shi, Tiantian Zhang, Bijiang Geng, Jingjing Mao, Jiqianzhu Zhang, Yijun Tian, Haoneng Wang, Fangyuan Gao, Xiaoyu Dai, Jinfeng Li, Jing Gu, Yun Chen, Xiaofang Zhang, Jikuai Chen, Jiangbo Zhu | | Drug and Chemical Toxicology. 2022; : 1 | | [Pubmed] | [DOI] | | | 22 |
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria |
|
| Marcus Maurer, William Berger, Ana Giménez-Arnau, Koremasa Hayama, Vipul Jain, Adam Reich, Sibylle Haemmerle, Karine Lheritier, Pauline Walsh, Summer Xia, Julian Storim | | Journal of Allergy and Clinical Immunology. 2022; | | [Pubmed] | [DOI] | | | 23 |
Antihistamines in children: A dermatological perspective |
|
| Sakshi Kohli, Richa Tayal, Tarang Goyal | | Indian Journal of Paediatric Dermatology. 2022; 23(1): 8 | | [Pubmed] | [DOI] | | | 24 |
Fexofenadine HCl Microspheres – Can it be the First Line therapy for Allergic Disorders ? |
|
| Paroma Arefin, Md Shehan Habib, Mohammad Mostafa, Dipankar Chakraborty, reebash Chandra Bhattacharjee, Md Saidul Arefin, Debabrata Karmakar | | Biosciences Biotechnology Research Asia. 2021; 18(4): 795 | | [Pubmed] | [DOI] | | | 25 |
Management of adult asthma and chronic rhinitis as one airway disease |
|
| Angelica Tiotiu, Plamena Novakova, Guidos Guillermo, Jaime Correira de Sousa, Fulvio Braido | | Expert Review of Respiratory Medicine. 2021; 15(9): 1135 | | [Pubmed] | [DOI] | | | 26 |
Antihistamine safety in older adult dermatologic patients |
|
| Madison Grinnell, Kyla N. Price, Amit Shah, Daniel C. Butler | | Journal of the American Academy of Dermatology. 2021; | | [Pubmed] | [DOI] | | | 27 |
Can ocean warming alter sub-lethal effects of antiepileptic and antihistaminic pharmaceuticals in marine bivalves? |
|
| Ângela Almeida, Vânia Calisto, Valdemar I. Esteves, Rudolf J. Schneider, Etelvina Figueira, Amadeu M.V.M. Soares, Rosa Freitas | | Aquatic Toxicology. 2021; 230: 105673 | | [Pubmed] | [DOI] | | | 28 |
Emergency medicine updates: Anaphylaxis |
|
| Brit Long, Michael Gottlieb | | The American Journal of Emergency Medicine. 2021; 49: 35 | | [Pubmed] | [DOI] | | | 29 |
Levocetirizine and Montelukast in the COVID-19 Treatment Paradigm |
|
| Bruce Chandler May, Kathleen Holly Gallivan | | International Immunopharmacology. 2021; : 108412 | | [Pubmed] | [DOI] | | | 30 |
Pre-procedural Preparation and Sedation for Gastrointestinal Endoscopy in Patients with Advanced Liver Disease |
|
| Brian M. Fung, Deanna J. Leon, Lauren N. Beck, James H. Tabibian | | Digestive Diseases and Sciences. 2021; | | [Pubmed] | [DOI] | | | 31 |
Efficacy of Triprolidine in the Treatment of Temporary Sleep Disturbance |
|
| Ana Santos Cravo, Adrian Shephard, Tim Shea | | The Journal of Clinical Pharmacology. 2021; 61(9): 1156 | | [Pubmed] | [DOI] | | | 32 |
Managing Chronic Urticaria and Recurrent Angioedema Differently with Advancing Age |
|
| Hilary J. Longhurst, Margarida Gonçalo, Kiran Godse, Luis F. Ensina | | The Journal of Allergy and Clinical Immunology: In Practice. 2021; 9(6): 2186 | | [Pubmed] | [DOI] | | | 33 |
The effect of antihistamines drugs on the functional activity of neutrophils |
|
| N. G Plekhova, I. N Dubnyak, E. V Eliseeva | | Genes & Cells. 2021; 16(1): 53 | | [Pubmed] | [DOI] | | | 34 |
Assessment of receptor affinities of ophthalmic and systemic agents in dry eye disease |
|
| Patrick Janeczko, Matthew R. Norris, Leonard Bielory | | Current Opinion in Allergy & Clinical Immunology. 2021; 21(5): 480 | | [Pubmed] | [DOI] | | | 35 |
Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis |
|
| Eli O. Meltzer, Nelson Augusto Rosario, Hugo Van Bever, Luiz Lucio | | Allergy, Asthma & Clinical Immunology. 2021; 17(1) | | [Pubmed] | [DOI] | | | 36 |
Lipid Cubic Systems for Sustained and Controlled Delivery of Antihistamine Drugs |
|
| Michele Dully, Miriama Ceresnakova, David Murray, Tewfik Soulimane, Sarah P. Hudson | | Molecular Pharmaceutics. 2021; 18(10): 3777 | | [Pubmed] | [DOI] | | | 37 |
Cetirizine-induced psychosis in a young adult with erythema multiforme |
|
| David Croitoru, Stephanie G Brooks, Vincent Piguet, Lindsey MacGillivray | | BMJ Case Reports. 2021; 14(2): e241393 | | [Pubmed] | [DOI] | | | 38 |
No Time for Lullabies: Tracing down Pharmacological Effects & Uses of H1-Antihistamines in Children Younger than 6?Years |
|
| Alaa Yehya, Mohammad Numan, Laila Matalqah | | Global Pediatric Health. 2021; 8: 2333794X21 | | [Pubmed] | [DOI] | | | 39 |
Modern possibilities of pathogenetic therapy of patients with allergic rhinitis |
|
| V. M. Svistushkin, G. N. Nikiforova, P. S. Artamonova, E. A. Shevchik | | Meditsinskiy sovet = Medical Council. 2020; (6): 101 | | [Pubmed] | [DOI] | | | 40 |
Depression Related Pathophysiologies Relevant in Heart Disease: Insights into the Mechanism Based on Pharmacological Treatments |
|
| Treesa P. Varghese, Anand V. Kumar, Nila M. Varghese, Sharad Chand | | Current Cardiology Reviews. 2020; 16(2): 125 | | [Pubmed] | [DOI] | | | 41 |
The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study |
|
| Annet Bens, Christian Dehlendorff, Søren Friis, Deirdre Cronin-Fenton, Maj-Britt Jensen, Bent Ejlertsen, Timothy L. Lash, Niels Kroman, Lene Mellemkjær | | British Journal of Cancer. 2020; 122(7): 1102 | | [Pubmed] | [DOI] | | | 42 |
Antihistamines and Ovarian Cancer Survival: Nationwide Cohort Study and in Vitro Cell Viability Assay |
|
| Freija Verdoodt, Christian Dehlendorff, Marja Jäättelä, Robert Strauss, Anton Pottegård, Jesper Hallas, Søren Friis, Susanne K Kjaer | | JNCI: Journal of the National Cancer Institute. 2020; 112(9): 964 | | [Pubmed] | [DOI] | | | 43 |
An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria |
|
| Sandeep Lal Vijayalal, Sandeep Arora, Rajeshwari Dabas, Manasa Shettisara Janney, Sushma Jankal Basavarajappa, Niyor M. Das | | Dermatologic Therapy. 2020; 33(6) | | [Pubmed] | [DOI] | | | 44 |
Psychotropic Drugs Show Anticancer Activity by Disrupting Mitochondrial and Lysosomal Function |
|
| Marco Varalda, Annamaria Antona, Valentina Bettio, Konkonika Roy, Ajay Vachamaram, Vaibhav Yellenki, Alberto Massarotti, Gianluca Baldanzi, Daniela Capello | | Frontiers in Oncology. 2020; 10 | | [Pubmed] | [DOI] | | | 45 |
Histamine |
|
| MEA Kemp | | Southern African Journal of Anaesthesia and Analgesia. 2020; : S86 | | [Pubmed] | [DOI] | | | 46 |
Histamine pharmacology: from Sir Henry Dale to the 21st century |
|
| Ekaterini Tiligada, Madeleine Ennis | | British Journal of Pharmacology. 2020; 177(3): 469 | | [Pubmed] | [DOI] | | | 47 |
Antihistamines are synergistic with Bruton’s tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells |
|
| Aaron Chanas-Larue, Gloria E. Villalpando-Rodriguez, Elizabeth S. Henson, James B. Johnston, Spencer B. Gibson | | Leukemia Research. 2020; 96: 106423 | | [Pubmed] | [DOI] | | | 48 |
An interim internal Threshold of Toxicologic Concern (iTTC) for chemicals in consumer products, with support from an automated assessment of ToxCast™ dose response data |
|
| Karen L. Blackburn, Gregory Carr, Jane L. Rose, Bastian G. Selman | | Regulatory Toxicology and Pharmacology. 2020; 114: 104656 | | [Pubmed] | [DOI] | | | 49 |
Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure–Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H1 Receptor Inverse Agonist |
|
| Manjinder S. Lall, Asser Bassyouni, James Bradow, Maria Brown, Mark Bundesmann, Jinshan Chen, Gregory Ciszewski, Anne E. Hagen, Dennis Hyek, Stephen Jenkinson, Bo Liu, R. Scott Obach, Senliang Pan, Usa Reilly, Neal Sach, Daniel J. Smaltz, Douglas K. Spracklin, Jeremy Starr, Melissa Wagenaar, Gregory S. Walker | | Journal of Medicinal Chemistry. 2020; 63(13): 7268 | | [Pubmed] | [DOI] | | | 50 |
Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers |
|
| Salvatore Febbraro, Tim Shea, Ana Santos Cravo | | Clinical Pharmacology in Drug Development. 2020; 9(4): 486 | | [Pubmed] | [DOI] | | | 51 |
Synthetic Strategy Studies for a Concise Access to Functionalized Pyrano[4,3-
b
]pyridin-7-ones: An Entry to Semi-Rigid Analogs of Antihistamines
|
|
| Anissa Beghennou, Kevin Passador, Anthony Passador, Vincent Corcé, Serge Thorimbert, Candice Botuha | | European Journal of Organic Chemistry. 2020; 2020(36): 5880 | | [Pubmed] | [DOI] | | | 52 |
Voltage-dependent modulation of TRPA1 currents by diphenhydramine |
|
| Xianfeng Shen, Qiaochu Wang, Yakang Lin, Koti Sreekrishna, Zhiyuan Jian, Michael X. Zhu, Jinbin Tian | | Cell Calcium. 2020; 90: 102245 | | [Pubmed] | [DOI] | | | 53 |
Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis |
|
| Marcus S. Shaker, Dana V. Wallace, David B.K. Golden, John Oppenheimer, Jonathan A. Bernstein, Ronna L. Campbell, Chitra Dinakar, Anne Ellis, Matthew Greenhawt, David A. Khan, David M. Lang, Eddy S. Lang, Jay A. Lieberman, Jay Portnoy, Matthew A. Rank, David R. Stukus, Julie Wang, Natalie Riblet, Aiyana M.P. Bobrownicki, Teresa Bontrager, Jarrod Dusin, Jennifer Foley, Becky Frederick, Eyitemi Fregene, Sage Hellerstedt, Ferdaus Hassan, Kori Hess, Caroline Horner, Kelly Huntington, Poojita Kasireddy, David Keeler, Bertha Kim, Phil Lieberman, Erin Lindhorst, Fiona McEnany, Jennifer Milbank, Helen Murphy, Oriana Pando, Ami K. Patel, Nicole Ratliff, Robert Rhodes, Kim Robertson, Hope Scott, Audrey Snell, Rhonda Sullivan, Varahi Trivedi, Azadeh Wickham, Marcus S. Shaker, Dana V. Wallace, Marcus S. Shaker, Dana V. Wallace, Jonathan A. Bernstein, Ronna L. Campbell, Chitra Dinakar, Anne Ellis, David B.K. Golden, Matthew Greenhawt, Jay A. Lieberman, Matthew A. Rank, David R. Stukus, Julie Wang, | | Journal of Allergy and Clinical Immunology. 2020; 145(4): 1082 | | [Pubmed] | [DOI] | | | 54 |
Self-reported generalised pruritus among community-dwelling older adults in Malaysia |
|
| Shin Shen Yong, Zhenli Kwan, Chin Chwen Ch’ng, Adrian Sze Wai Yong, Leng Leng Tan, Winn Hui Han, Shahrul Bahyah Kamaruzzaman, Ai-Vyrn Chin, Maw Pin Tan | | BMC Geriatrics. 2020; 20(1) | | [Pubmed] | [DOI] | | | 55 |
Towards definitive management of allergic rhinitis: best use of new and established therapies |
|
| Lubnaa Hossenbaccus, Sophia Linton, Sarah Garvey, Anne K. Ellis | | Allergy, Asthma & Clinical Immunology. 2020; 16(1) | | [Pubmed] | [DOI] | | | 56 |
Recombinant human hyaluronidase PH20-mediated dermal spreading activity in mice is not altered by steroids, antihistamines, or salicylic acid |
|
| Jessica A. Cowell, Marie A. Printz, Curtis B. Thompson | | Drug Metabolism and Personalized Therapy. 2020; 0(0) | | [Pubmed] | [DOI] | | | 57 |
Antihistamines in the treatment of allergic rhinitis |
|
| A. L. Guseva, M. L. Derbeneva | | Meditsinskiy sovet = Medical Council. 2020; (6): 90 | | [Pubmed] | [DOI] | | | 58 |
Real world Indian experience of switchover to Bilastine in CSU patient refractory to other antihistamines |
|
| Dhiraj Dhoot, Bela Shah, DBN Murthy, Atul Kochhar, Rashmi KM | | IP Indian Journal of Clinical and Experimental Dermatology. 2020; 6(4): 328 | | [Pubmed] | [DOI] | | | 59 |
Efficacy and safety of rupatadine in Japanese patients with seasonal allergic rhinitis: A double-blind, randomized, multicenter, placebo-controlled clinical trial |
|
| Kimihiro Okubo, Takamasa Suzuki, Ayaka Tanaka, Hiroshi Aoki | | Allergology International. 2019; 68(2): 207 | | [Pubmed] | [DOI] | | | 60 |
pH-Dependent Uptake and Sublethal Effects of Antihistamines in Zebrafish (
Danio rerio
) Embryos
|
|
| Lisa Bittner, Elisabet Teixidó, Isabel Keddi, Beate I. Escher, Nils Klüver | | Environmental Toxicology and Chemistry. 2019; 38(5): 1012 | | [Pubmed] | [DOI] | | | 61 |
Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema |
|
| Uwe Matterne, Merle Margarete Böhmer, Elke Weisshaar, Aldrin Jupiter, Ben Carter, Christian J Apfelbacher | | Cochrane Database of Systematic Reviews. 2019; 2019(1) | | [Pubmed] | [DOI] | | | 62 |
Pharmacokinetics of hydroxyzine and cetirizine following oral administration of hydroxyzine to exercised Thoroughbred horses |
|
| Heather K. Knych, Daniel Weiner, Stacy Steinmetz, Katherine Flynn, Daniel S. McKemie | | Journal of Veterinary Pharmacology and Therapeutics. 2019; 42(6): 617 | | [Pubmed] | [DOI] | | | 63 |
Sleep modulating agents |
|
| Younggi Choi, Brian K. Raymer | | Bioorganic & Medicinal Chemistry Letters. 2019; 29(16): 2025 | | [Pubmed] | [DOI] | | | 64 |
Antibacterial Activity of Rhinacanthus nasutus L. Kurz ointment to Inhibit Staphylococcus aureus Growth Using In Vitro Dilution Method |
|
| Betty Lukiati, Nugrahaningsih, Sitoresmi Prabaningtyas, Dina Aribah, Siti Nur Arifah | | IOP Conference Series: Earth and Environmental Science. 2019; 276(1): 012023 | | [Pubmed] | [DOI] | | | 65 |
A Survey of the Structures of US FDA Approved Combination Drugs |
|
| Pradipta Das, Michael D. Delost, Munaum H. Qureshi, David T. Smith, Jon T. Njardarson | | Journal of Medicinal Chemistry. 2019; 62(9): 4265 | | [Pubmed] | [DOI] | | | 66 |
Route to Prolonged Residence Time at the Histamine H1 Receptor: Growing from Desloratadine to Rupatadine |
|
| Reggie Bosma, Zhiyong Wang, Albert J. Kooistra, Nick Bushby, Sebastiaan Kuhne, Jelle van den Bor, Michael J. Waring, Chris de Graaf, Iwan J. de Esch, Henry F. Vischer, Robert J. Sheppard, Maikel Wijtmans, Rob Leurs | | Journal of Medicinal Chemistry. 2019; 62(14): 6630 | | [Pubmed] | [DOI] | | | 67 |
Allergic disease - options of self-medication |
|
| Hana Kotolová | | Praktické lékárenství. 2018; 14(1): 22 | | [Pubmed] | [DOI] | | | 68 |
A fully validated method for the simultaneous determination of 11 antihistamines in breast milk by gas chromatography–mass spectrometry |
|
| Maria Katselou, Sotiris Athanaselis, Panagiota Nikolaou, Samir Qammaz, Artemisia Dona, Chara Spiliopoulou, Ioannis Papoutsis | | Biomedical Chromatography. 2018; 32(8) | | [Pubmed] | [DOI] | | | 69 |
Bioanalysis of antihistamines for clinical or forensic purposes |
|
| Maria Katselou, Ioannis Papoutsis, Panagiota Nikolaou, Chara Spiliopoulou, Sotiris Athanaselis | | Biomedical Chromatography. 2017; 31(1) | | [Pubmed] | [DOI] | | | 70 |
Second generation H1 - antihistamines interaction with food and alcohol—A systematic review |
|
| Pawel Pasko, Tomasz Rodacki, Renata Domagala-Rodacka, Krzysztof Palimonka, Monika Marcinkowska, Danuta Owczarek | | Biomedicine & Pharmacotherapy. 2017; 93: 27 | | [Pubmed] | [DOI] | | | 71 |
Can human allergy drug fexofenadine, an antagonist of histamine (H1) receptor, be used to treat dog and cat? Homology modeling, docking and molecular dynamic Simulation of three H1 receptors in complex with fexofenadine |
|
| Safaa Sader, Jun Cai, Anna C.G. Muller, Chun Wu | | Journal of Molecular Graphics and Modelling. 2017; 75: 106 | | [Pubmed] | [DOI] | | | 72 |
Levocetirizine in clinical practice of allergist |
|
| O G Elisyutina, O V Shtyrbul | | Russian Journal of Allergy. 2016; 13(3): 49 | | [Pubmed] | [DOI] | | | 73 |
Management of Chronic Spontaneous Urticaria in the Elderly |
|
| Maria Teresa Ventura,Nicoletta Cassano,Paolo Romita,Michelangelo Vestita,Caterina Foti,Gino Antonio Vena | | Drugs & Aging. 2015; | | [Pubmed] | [DOI] | | | 74 |
Update on Antihistamine Treatment for Chronic Urticaria in Children |
|
| Anna Belloni Fortina,Elena Fontana | | Current Treatment Options in Allergy. 2014; | | [Pubmed] | [DOI] | | | 75 |
Effects of oral intake of cetirizine HCl and desloratadine molecules on the middle ear mucosa: an experimental animal study |
|
| Murat Songu,Yilmaz Ozkul,Seyithan Kirtay,Secil Arslanoglu,Mahmut Ozkut,Sevinc Inan,Kazim Onal | | European Archives of Oto-Rhino-Laryngology. 2014; 271(4): 833 | | [Pubmed] | [DOI] | | | 76 |
Treatment of itch in allergic dermatoses |
|
| Y N Perlamutrov, K B Olkhovskaya | | Russian Journal of Allergy. 2014; 11(1): 69 | | [Pubmed] | [DOI] | | | 77 |
Polyfunctional antiallergic potencies of ?-antihistamine levocetirizine |
|
| I S Gushchin | | Russian Journal of Allergy. 2014; 11(2): 11 | | [Pubmed] | [DOI] | | | 78 |
Treatment of Antipsychotic-Induced Sialorrhea |
|
| Amy R. Glick,Imran A. Khan,Leo Sher | | Psychiatric Annals. 2014; 44(6): 267 | | [Pubmed] | [DOI] | | | 79 |
EFFICACY AND SAFETY OF DIMETHINDENE MALEATE IN CLINICAL PRACTICE |
|
| E S Fedenko, O G Elisyutina, N I Ilina | | Russian Journal of Allergy. 2013; 10(6): 64 | | [Pubmed] | [DOI] | | | 80 |
Antihistamines in pediatrics |
|
| Unni, J.C. | | Source of the Document Indian Journal of Practical Pediatrics. 2013; | | [Pubmed] | |
|
|
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 36190 | | | Printed | 524 | | | Emailed | 2 | | | PDF Downloaded | 680 | | | Comments | [Add] | | | Cited by others | 80 | | |
|
|
